Literature DB >> 20962539

No role for melanoma treatment in the association between melanoma and amyotrophic lateral sclerosis or Parkinson's disease.

Peter D Baade, Elena Herrero Hernández, D Michal Freedman, B Mark Smithers, Lin Fritschi.   

Abstract

Entities:  

Mesh:

Year:  2010        PMID: 20962539      PMCID: PMC2974840          DOI: 10.1159/000321177

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


× No keyword cloud information.
  10 in total

1.  Urban-rural differences in survival from cutaneous melanoma in Queensland.

Authors:  Michael Coory; Mark Smithers; Joanne Aitken; Peter Baade; Ian Ring
Journal:  Aust N Z J Public Health       Date:  2006-02       Impact factor: 2.939

Review 2.  Neurologic complications of cancer chemotherapy.

Authors:  Joohee K Sul; Lisa M Deangelis
Journal:  Semin Oncol       Date:  2006-06       Impact factor: 4.929

3.  Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis.

Authors:  Yue-Mei Jiang; Masahiko Yamamoto; Yasushi Kobayashi; Tsuyoshi Yoshihara; Yideng Liang; Shinichi Terao; Hideyuki Takeuchi; Shinsuke Ishigaki; Masahisa Katsuno; Hiroaki Adachi; Jun-ichi Niwa; Fumiaki Tanaka; Manabu Doyu; Mari Yoshida; Yoshio Hashizume; Gen Sobue
Journal:  Ann Neurol       Date:  2005-02       Impact factor: 10.422

4.  A TRPM7 variant shows altered sensitivity to magnesium that may contribute to the pathogenesis of two Guamanian neurodegenerative disorders.

Authors:  Meredith C Hermosura; Hannah Nayakanti; Maxim V Dorovkov; Fernanda R Calderon; Alexey G Ryazanov; David S Haymer; Ralph M Garruto
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-28       Impact factor: 11.205

5.  Mortality due to amyotrophic lateral sclerosis and Parkinson's disease among melanoma patients.

Authors:  P D Baade; L Fritschi; D M Freedman
Journal:  Neuroepidemiology       Date:  2007       Impact factor: 3.282

6.  Amyotrophic lateral sclerosis mortality in 1.9 million US cancer survivors.

Authors:  D Michal Freedman; Lois B Travis; Gloria Gridley; Ralph W Kuncl
Journal:  Neuroepidemiology       Date:  2005-08-15       Impact factor: 3.282

Review 7.  Neurological adverse effects caused by cytotoxic and targeted therapies.

Authors:  David Schiff; Patrick Y Wen; Martin J van den Bent
Journal:  Nat Rev Clin Oncol       Date:  2009-08-25       Impact factor: 66.675

Review 8.  TRPM7 and TRPM2-Candidate susceptibility genes for Western Pacific ALS and PD?

Authors:  Meredith C Hermosura; Ralph M Garruto
Journal:  Biochim Biophys Acta       Date:  2007-02-24

9.  Final version of 2009 AJCC melanoma staging and classification.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Michael B Atkins; David R Byrd; Antonio C Buzaid; Alistair J Cochran; Daniel G Coit; Shouluan Ding; Alexander M Eggermont; Keith T Flaherty; Phyllis A Gimotty; John M Kirkwood; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Arthur J Sober; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

10.  Genetic determinants of hair color and Parkinson's disease risk.

Authors:  Xiang Gao; Kelly C Simon; Jiali Han; Michael A Schwarzschild; Alberto Ascherio
Journal:  Ann Neurol       Date:  2009-01       Impact factor: 10.422

  10 in total
  3 in total

1.  The Effect of Different Types of Nanoparticles on FUS and TDP-43 Solubility and Subcellular Localization.

Authors:  Jasna Lojk; Sonja Prpar Mihevc; Vladimir Boštjan Bregar; Mojca Pavlin; Boris Rogelj
Journal:  Neurotox Res       Date:  2017-04-25       Impact factor: 3.911

Review 2.  Meta-analysis of the relationship between Parkinson disease and melanoma.

Authors:  Rui Liu; Xiang Gao; Yi Lu; Honglei Chen
Journal:  Neurology       Date:  2011-06-07       Impact factor: 9.910

3.  The association between cancer and amyotrophic lateral sclerosis.

Authors:  D Michal Freedman; Rochelle E Curtis; Sarah E Daugherty; James J Goedert; Ralph W Kuncl; Margaret A Tucker
Journal:  Cancer Causes Control       Date:  2012-10-23       Impact factor: 2.506

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.